Vnus Buy Latest Big Win for 2004 Device IPO Class

The medical device industry broke the IPO ice in 2004, sending 17 companies onto the US public markets. How have they fared?

In this season of commencements and keynote addresses, the acquisition of VNUS Medical Technologies Inc. by Covidien Ltd. brought us back to the notable medical device IPO class of 2004. Five years ago, these 17 medical device companies ended the sector’s 7-year initial public offering drought, which set in following the disappointing group of device companies that went public in 1995-96.

More from Archive

Final Chance To Have Your Say: Take Scrip's Reader Survey This Week

 

Editor’s note: This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.

Shape Our Content: Take The Reader Survey

 

Editor’s note: We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in the coverage topics, content format or the method in which you receive and access Scrip, or if you love it how it is, now is the time to have your voice heard.

Galapagos Expands Point-Of-Care CAR-T Study To The US

 

CEO Paul Stoffels said gaining US clearance for an IND for its novel CAR-T product was demanding, but now opens up a pathway towards a pivotal study starting in 2025.

Analysts Split On Eisai’s Chances Of Changing EU Regulator’s Mind On Leqembi

 

A final rejection of Leqembi could also spell the same fate for Lilly’s rival drug but public outcry and demand for Alzheimer’s therapies might force the regulator’s hand

More from Scrip

Pipeline Watch: Ten Approvals And Eighteen Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Latigo Raises $150m To Drive Its First Pain Drug Toward Phase III

 
• By 

Vertex has the first-in-class NaV1.8 inhibitor for acute pain, Journavx, but Latigo plans to bring forward multiple best-in-class options for acute and chronic pain against NaV1.8 and other targets.

MSD’s CIDO Williams: ‘We Must Shorten Technology Adoption Cycles’

 

MSD's chief information & digital officer emphasizes the need for pharma to accelerate technology adoption cycles to ensure drugs reach patients faster. The role of a robust digital backbone for seamless data flow, leadership commitment in digital transformation and an upcoming technology center in Hyderabad are other aspects he discussed.